Venous Thromboembolism: A Need for More Public Awareness and Research Into Mechanisms

Moll, Stephan; Mackman, Nigel

doi:10.1161/atvbaha.108.163097

Cited by 25 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,12,[25][26][27][28] The most common site for the development of venous thrombi is valve pockets. 26,27,[29][30][31][32] A number of different mouse models have been used to study thrombosis. 33 In general, animal models of thrombosis that do not produce extensive damage to the vessel wall are better models of venous thrombosis than models that expose vessel wall TF.…”

Section: Development Of a Venous Thrombusmentioning

confidence: 99%

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Geddings

Mackman

2013

Blood

Self Cite

289

238

View full text Add to dashboard Cite

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different cancer types have different rates of thrombosis, with pancreatic cancer having one of the highest rates. However, the mechanisms responsible for the increase in venous thrombosis in patients with cancer are not understood. Tissue factor (TF) is a transmembrane receptor and primary initiator of blood coagulation. Tumor cells express TF and spontaneously release TF-positive microparticles (MPs) into the blood. MPs are small membrane vesicles that are highly procoagulant. It has been proposed that these circulating tumor-derived, TF-positive MPs may explain the increased rates of venous thrombosis seen in patients with cancer. In animal models, increased levels of tumor-derived, TF-positive MPs are associated with activation of coagulation. Moreover, these MPs bind to sites of vascular injury and enhance thrombosis. We and others have found that patients with cancer have elevated levels of circulating TF-positive MPs. These MPs are derived from tumors because they express tumor markers and are decreased by tumor resection. Importantly, several studies have shown that increased levels of TF-positive MPs correlate with venous thrombosis in patients with cancer. Taken together, these results suggest that TF-positive MPs may be a useful biomarker to identify patients with cancer who are at high risk for thrombosis.

show abstract

Section: Development Of a Venous Thrombusmentioning

confidence: 99%

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Geddings

Mackman

2013

Blood

Self Cite

289

238

View full text Add to dashboard Cite

show abstract

“…El TEV es considerado actualmente un problema de salud pública que requiere la implementación urgente de medidas preventivas para disminuir su costo humano y económico [25][26][27] . Las consecuencias negativas no sólo resultan de los efectos del evento agudo (mortalidad, estadías hospitalarias prolongadas) sino también de complicaciones tardías como recurrencias 28 , hipertensión pulmonar 29 y síndrome postrombótico 30 , que pueden afectar significativamente la calidad de vida de los pacientes.…”

Section: Discussionunclassified

Frecuencia de tromboembolismo venoso en pacientes hospitalizados con cáncer. Factores de riesgo y eficacia de la tromboprofilaxis farmacológica

2008

Rev. méd. Chile

View full text Add to dashboard Cite

“…Venous valves have adapted to this phenomenon by expressing higher levels of TM and EPCR (32). However, despite this additional protection, valve pockets are thought to be the most common site of thrombosis (33). Recent studies have investigated the role of TF in venous thrombosis.…”

Section: Venous Thrombosismentioning

confidence: 99%

Role of Tissue Factor in Venous Thrombosis

Manly

Boles

Mackman

2011

Annu. Rev. Physiol.

Self Cite

112

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide. However, the mechanisms by which clots are formed in the deep veins have not been determined. Tissue factor (TF) is the primary initiator of the coagulation cascade and is essential for hemostasis. Under pathological conditions, TF is released into the circulation on small-membrane vesicles termed microparticles (MPs). Recent studies suggest that elevated levels of MPTF may trigger thrombosis. This review provides an overview of the role of TF in VTE.

show abstract

Venous Thromboembolism: A Need for More Public Awareness and Research Into Mechanisms

Cited by 25 publications

References 7 publications

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients

Frecuencia de tromboembolismo venoso en pacientes hospitalizados con cáncer. Factores de riesgo y eficacia de la tromboprofilaxis farmacológica

Role of Tissue Factor in Venous Thrombosis

Contact Info

Product

Resources

About